2024
Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal
D’Onofrio G, Herring A, Perrone J, Hawk K, Samuels E, Cowan E, Anderson E, McCormack R, Huntley K, Owens P, Martel S, Schactman M, Lofwall M, Walsh S, Dziura J, Fiellin D. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal. JAMA Network Open 2024, 7: e2420702. PMID: 38976265, PMCID: PMC11231806, DOI: 10.1001/jamanetworkopen.2024.20702.Peer-Reviewed Original ResearchConceptsClinical Opiate Withdrawal ScaleExtended-release buprenorphineOpioid use disorderPrecipitated withdrawalOpioid withdrawalOpioid use disorder treatmentCow scoreClinical Opiate Withdrawal Scale scoreAdverse eventsNonrandomized trialsSevere opioid use disorderDays of opioid useOpiate Withdrawal ScaleModerate to severe opioid use disorderFormulation of buprenorphineOpioid use disorder careWithdrawal ScaleUse disorderAssociated with medicationsNonprescribed opioidsPain scoresExtended-releaseInjection painOpioid useAdult patientsAccessibility of Opioid Treatment Programs Based on Conventional vs Perceived Travel Time Measures
Kim J, Lee J, Thornhill T, Dennett J, Lu H, Howell B, Grau L, Fiellin D, Heimer R, Gonsalves G. Accessibility of Opioid Treatment Programs Based on Conventional vs Perceived Travel Time Measures. JAMA Network Open 2024, 7: e240209. PMID: 38376839, PMCID: PMC10879949, DOI: 10.1001/jamanetworkopen.2024.0209.Peer-Reviewed Original ResearchConceptsTransit travel timeAccessibility metricsTravel timeTravel componentsAccessibility scoresTransportation burdenTravel burdenOut-of-vehicleComponents of travelConventional accessibility measuresSpatial regression modelsTravel time measurementsPublic transitTransit schedulesAccessibility measuresDeparture timeTravel time analysisTrip durationTravelOperating hoursTime analysisCross-sectional studyOpioid use disorderPolicy recommendationsDecision-makingImplementing a pharmacist-integrated collaborative model of medication treatment for opioid use disorder in primary care: study design and methodological considerations
McLeman B, Gauthier P, Lester L, Homsted F, Gardner V, Moore S, Joudrey P, Saldana L, Cochran G, Harris J, Hefner K, Chongsi E, Kramer K, Vena A, Ottesen R, Gallant T, Boggis J, Rao D, Page M, Cox N, Iandiorio M, Ambaah E, Ghitza U, Fiellin D, Marsch L. Implementing a pharmacist-integrated collaborative model of medication treatment for opioid use disorder in primary care: study design and methodological considerations. Addiction Science & Clinical Practice 2024, 19: 18. PMID: 38500166, PMCID: PMC10949656, DOI: 10.1186/s13722-024-00452-y.Peer-Reviewed Original ResearchConceptsStages of Implementation CompletionPrimary care sitesOpioid use disorderCare sitesConsolidated Framework for Implementation ResearchPatient electronic health record dataCollaborative model of careTreatment of opioid use disorderElectronic health record dataPrimary care teamsCollaborative care modelModels of careHealth record dataOpioid use disorder careUse disorderImplementation facilitatorsCare modelCare teamPrimary careImplementation researchDiscussionThis studyDispensed medicationsPharmacy techniciansInterpretation of findingsImplementation Completion
2023
Receipt of opioid use disorder treatments prior to fatal overdoses and comparison to no treatment in Connecticut, 2016–17
Heimer R, Black A, Lin H, Grau L, Fiellin D, Howell B, Hawk K, D'Onofrio G, Becker W. Receipt of opioid use disorder treatments prior to fatal overdoses and comparison to no treatment in Connecticut, 2016–17. Drug And Alcohol Dependence 2023, 254: 111040. PMID: 38043226, PMCID: PMC10872282, DOI: 10.1016/j.drugalcdep.2023.111040.Peer-Reviewed Original ResearchConceptsNon-medication treatmentsRelative riskOpioid overdose deathsIncidence rateMOUD treatmentOverdose deathsOpioid use disorder treatmentResults Incidence ratesRetrospective cohort studyDifferent treatment modalitiesPopulation-level effortsUse disorder treatmentFatal opioid poisoningsCohort studyOpioid poisoningTreatment modalitiesConclusion ExposurePoisoning deathsFatal overdosesTreatment exposureDisorder treatmentDeathTreatmentMethadoneRiskComputational phenotypes for patients with opioid-related disorders presenting to the emergency department
Taylor R, Gilson A, Schulz W, Lopez K, Young P, Pandya S, Coppi A, Chartash D, Fiellin D, D’Onofrio G. Computational phenotypes for patients with opioid-related disorders presenting to the emergency department. PLOS ONE 2023, 18: e0291572. PMID: 37713393, PMCID: PMC10503758, DOI: 10.1371/journal.pone.0291572.Peer-Reviewed Original ResearchConceptsSubstance use disordersUse disordersED visitsPatient presentationCarlson comorbidity indexOpioid-related diagnosesOpioid-related disordersOne-year survivalRate of medicationOpioid use disorderElectronic health record dataPatient-oriented outcomesYears of ageHealth record dataChronic substance use disordersED returnComorbidity indexAcute overdoseMedical managementClinical entityRetrospective studyEmergency departmentChronic conditionsInclusion criteriaUnique cohortAlcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy
Cartwright E, Pierret C, Minassian C, Esserman D, Tate J, Goetz M, Bhattacharya D, Fiellin D, Justice A, Re V, Rentsch C. Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy. JAMA Network Open 2023, 6: e2335715. PMID: 37751206, PMCID: PMC10523171, DOI: 10.1001/jamanetworkopen.2023.35715.Peer-Reviewed Original ResearchConceptsSustained virologic responseAlcohol use disorderHigh-risk consumptionHistory of AUDLow-risk consumptionDAA therapyAlcohol use categoriesAlcohol useVirologic responseCohort studyAntiviral therapyOdds ratioChronic hepatitis C virus (HCV) infectionAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireHepatitis C virus infectionVeterans AffairsActing antiviral (DAA) therapyDAA treatment initiationHCV elimination goalsUndetectable HCV RNAC virus infectionFibrosis-4 scoreRetrospective cohort studyMultivariable logistic regressionTenth Revision diagnosisFacilitation and Preferred Models for Delivering Substance Use Disorder Treatment in HIV Clinics: Results From a Multisite Randomized Trial
Muvvala S, Gan G, Morford K, Dziura J, Esserman D, Porter E, Chan P, Cornman D, Reynolds J, Yager J, Fiellin D, Edelman E. Facilitation and Preferred Models for Delivering Substance Use Disorder Treatment in HIV Clinics: Results From a Multisite Randomized Trial. Journal Of Addiction Medicine 2023, 17: e388-e391. PMID: 37934538, PMCID: PMC10726383, DOI: 10.1097/adm.0000000000001192.Peer-Reviewed Original ResearchConceptsOpioid use disorderAlcohol use disorderTobacco use disorderHIV clinicUse disordersAddiction treatmentSubstance use disorder treatmentUse disorder treatmentMaintenance phaseRandomized trialsStaff preferencesImproved outcomesMultisite Randomized TrialImplementation facilitationDisorder treatmentControl phaseClinicCliniciansTreatment modelTreatmentDisordersSignificant differencesInterventionHigher proportionAddiction treatment modelsEfficacy of alcohol reduction interventions among people with HIV as evaluated by self-report and a phosphatidylethanol (PEth) outcome: protocol for a systematic review and individual participant data meta-analysis
Kane J, Allen I, Fatch R, Scheffler A, Emenyonu N, Puryear S, Chirayil P, So-Armah K, Kahler C, Magidson J, Conroy A, Edelman E, Woolf-King S, Parry C, Kiene S, Chamie G, Adong J, Go V, Cook R, Muyindike W, Morojele N, Blokhina E, Krupitsky E, Fiellin D, Hahn J. Efficacy of alcohol reduction interventions among people with HIV as evaluated by self-report and a phosphatidylethanol (PEth) outcome: protocol for a systematic review and individual participant data meta-analysis. BMJ Open 2023, 13: e070713. PMID: 37280036, PMCID: PMC10254608, DOI: 10.1136/bmjopen-2022-070713.Peer-Reviewed Original ResearchConceptsAlcohol useUnhealthy alcohol useSelf-reported measurementsAlcohol reduction interventionsEfficacy of interventionsAlcohol outcomesIndividual participant dataIntervention studiesAlcohol interventionsInformation biasesAdditional ethical approvalParticipants 15 yearsEffective interventionsSystematic reviewTreatment effectsParticipant dataHIV viral suppressionPrimary outcome variableReduction interventionsPooled treatment effectOutcome variablesInterventionInternational scientific meetingsSecondary outcomesViral suppressionContingency management with stepped care for unhealthy alcohol use among individuals with HIV: Protocol for a randomized controlled trial
Edelman E, Dziura J, Deng Y, DePhilippis D, Fucito L, Ferguson T, Bedimo R, Brown S, Marconi V, Goetz M, Rodriguez-Barradas M, Simberkoff M, Molina P, Weintrob A, Maisto S, Paris M, Justice A, Bryant K, Fiellin D. Contingency management with stepped care for unhealthy alcohol use among individuals with HIV: Protocol for a randomized controlled trial. Contemporary Clinical Trials 2023, 131: 107242. PMID: 37230168, PMCID: PMC10460633, DOI: 10.1016/j.cct.2023.107242.Peer-Reviewed Original ResearchConceptsUnhealthy alcohol useLong-term abstinenceAlcohol useContingency managementAlcohol consumptionFormal alcohol treatmentShort-term abstinenceMotivational enhancement therapyGOV IDENTIFIERSecondary outcomesWeek 24Primary outcomeWeek 12Preliminary efficacyTreatment trialsPhysician managementEfficacy trialsMedical conditionsAlcohol treatmentExploratory outcomesEnhancement therapyAbstinenceTrialsCareHealthy activitiesNational Institute on Drug Abuse Clinical Trials Network Meeting Report: Advancing Emergency Department Initiation of Buprenorphine for Opioid Use Disorder
Cowan E, Perrone J, Bernstein S, Coupet E, Fiellin D, Hawk K, Herring A, Huntley K, McCormack R, Venkatesh A, D'Onofrio G. National Institute on Drug Abuse Clinical Trials Network Meeting Report: Advancing Emergency Department Initiation of Buprenorphine for Opioid Use Disorder. Annals Of Emergency Medicine 2023, 82: 326-335. PMID: 37178101, PMCID: PMC10524880, DOI: 10.1016/j.annemergmed.2023.03.025.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsOpioid use disorderEmergency departmentUse disordersDrug Abuse Clinical Trials NetworkEffective evidence-based treatmentsEmergency department initiationStandard emergency careMajor public health crisisClinical Trials NetworkEvidence of efficacyNational InstituteEvidence-based treatmentsOpioid overdose deathsTechnology-based interventionsBuprenorphine dosingBuprenorphine initiationPeer-based interventionsPublic health crisisPatient outcomesED staffOverdose deathsEmergency careBuprenorphineTrials NetworkUniversal uptakeAssociations between Patient Experience and Addiction Treatment Facility Services: Results of the Addiction Treatment Locator, Assessment, and Standards Surveys
Chen K, Oldfield B, Joudrey P, Biegacki E, Fiellin D. Associations between Patient Experience and Addiction Treatment Facility Services: Results of the Addiction Treatment Locator, Assessment, and Standards Surveys. Journal Of Addiction Medicine 2023, 17: 544-550. PMID: 37788607, DOI: 10.1097/adm.0000000000001174.Peer-Reviewed Original ResearchPerspectives on and experiences of emergency department–initiated buprenorphine among clinical pharmacists: A multi-site qualitative study
Justen M, Edelman E, Chawarski M, Coupet E, Cowan E, Lyons M, Owens P, Martel S, Richardson L, Rothman R, Whiteside L, O'Connor P, Zahn E, D'Onofrio G, Fiellin D, Hawk K. Perspectives on and experiences of emergency department–initiated buprenorphine among clinical pharmacists: A multi-site qualitative study. Journal Of Substance Use And Addiction Treatment 2023, 155: 209058. PMID: 37149149, DOI: 10.1016/j.josat.2023.209058.Peer-Reviewed Original ResearchConceptsOpioid use disorderClinical pharmacistsED careEmergency department-initiated buprenorphineEffective OUD treatmentEffectiveness-implementation studyHealth Services frameworkFocus groups/interviewsMulti-site qualitative studyFuture implementation effortsOUD treatmentUrban EDGroups/interviewsEmergency departmentPromoting ActionUnique pharmacologyED staffBuprenorphinePharmacist participantsUse disordersED contextPharmacistsPractice changePharmacy resourcesSuccessful program implementationImplementing Programs to Initiate Buprenorphine for Opioid Use Disorder Treatment in High-Need, Low-Resource Emergency Departments: A Nonrandomized Controlled Trial
McCormack R, Rotrosen J, Gauthier P, D'Onofrio G, Fiellin D, Marsch L, Novo P, Liu D, Edelman E, Farkas S, Matthews A, Mulatya C, Salazar D, Wolff J, Knight R, Goodman W, Williams J, Hawk K. Implementing Programs to Initiate Buprenorphine for Opioid Use Disorder Treatment in High-Need, Low-Resource Emergency Departments: A Nonrandomized Controlled Trial. Annals Of Emergency Medicine 2023, 82: 272-287. PMID: 37140493, PMCID: PMC10524047, DOI: 10.1016/j.annemergmed.2023.02.013.Peer-Reviewed Original ResearchConceptsBuprenorphine programImplementation facilitationEmergency departmentMedical recordsOpioid use disorder treatmentMain secondary outcomesMore treatment visitsPrimary implementation outcomeNonrandomized Controlled TrialPatient-level outcomesPatients' medical recordsUse disorder treatmentTreatment 30 daysBuprenorphine administrationOpioid useSecondary outcomesControlled TrialsTreatment visitsED settingUnique patientsClinicians' readinessEligibility criteriaClinical protocolsDisorder treatmentOverdose eventsPerspectives of Clinicians and Staff at Community-Based Opioid Use Disorder Treatment Settings on Linkages With Emergency Department–Initiated Buprenorphine Programs
Sue K, Chawarski M, Curry L, McNeil R, Coupet E, Schwartz R, Wilder C, Tsui J, Hawk K, D’Onofrio G, O’Connor P, Fiellin D, Edelman E. Perspectives of Clinicians and Staff at Community-Based Opioid Use Disorder Treatment Settings on Linkages With Emergency Department–Initiated Buprenorphine Programs. JAMA Network Open 2023, 6: e2312718. PMID: 37163263, PMCID: PMC10173026, DOI: 10.1001/jamanetworkopen.2023.12718.Peer-Reviewed Original ResearchConceptsCommunity-based cliniciansOpioid use disorderEmergency departmentOUD treatmentMedication treatmentSubstance use disorders trainingUrban academic emergency departmentEffectiveness-implementation studyAcademic emergency departmentDisorder treatment settingsPerspectives of cliniciansCommunity-based treatmentCommunity-based treatment programsStaff perspectivesImplementation science frameworkBuprenorphine programTreatment cliniciansPeer navigatorsReferral sitesPromoting ActionMAIN OUTCOMEED staffBuprenorphineFocus groupsUse disordersDrive Time to Addiction Treatment Facilities Providing Contingency Management across Rural and Urban Census Tracts in 6 US States
Joudrey P, Chen K, Oldfield B, Biegacki E, Fiellin D. Drive Time to Addiction Treatment Facilities Providing Contingency Management across Rural and Urban Census Tracts in 6 US States. Journal Of Addiction Medicine 2023, 17: 615-617. PMID: 37788621, PMCID: PMC10591456, DOI: 10.1097/adm.0000000000001170.Peer-Reviewed Original ResearchConceptsMedian drive timeCM providersContingency managementMOUD servicesUrban census tractsOpioid use disorder servicesRural-Urban Commuting Area codesQualified health centersCensus tractsAddiction treatment facilitiesDisorder treatment providersDrive timeMOUD treatmentHealth centersOutpatient substanceDisorder servicesFacility surveyUrban-rural disparitiesTractTreatment providersFQHCsArea codesMinutesUS statesProvidersImplementation Facilitation to Promote Emergency Department–Initiated Buprenorphine for Opioid Use Disorder
D’Onofrio G, Edelman E, Hawk K, Chawarski M, Pantalon M, Owens P, Martel S, Rothman R, Saheed M, Schwartz R, Cowan E, Richardson L, Salsitz E, Lyons M, Freiermuth C, Wilder C, Whiteside L, Tsui J, Klein J, Coupet E, O’Connor P, Matthews A, Murphy S, Huntley K, Fiellin D. Implementation Facilitation to Promote Emergency Department–Initiated Buprenorphine for Opioid Use Disorder. JAMA Network Open 2023, 6: e235439. PMID: 37017967, PMCID: PMC10077107, DOI: 10.1001/jamanetworkopen.2023.5439.Peer-Reviewed Original ResearchConceptsOpioid use disorderRate of patientsOUD treatmentImplementation facilitationED visitsObservational cohortED cliniciansX-waiverUse disordersEmergency Department-Initiated BuprenorphineUntreated opioid use disorderEvaluation periodHybrid type 3Provision of buprenorphineBaseline periodGrand roundsRates of EDPrimary outcomeWhite patientsAcademic EDBlack patientsED patientsEmergency departmentCommunity cliniciansMAIN OUTCOMEAvailability of Specific Programs and Medications for Addiction Treatment to Vulnerable Populations: Results from the Addiction Treatment Locator, Assessment, and Standards (ATLAS) Survey
Oldfield B, Chen K, Joudrey P, Biegacki E, Fiellin D. Availability of Specific Programs and Medications for Addiction Treatment to Vulnerable Populations: Results from the Addiction Treatment Locator, Assessment, and Standards (ATLAS) Survey. Journal Of Addiction Medicine 2023, 17: 477-480. PMID: 37579115, DOI: 10.1097/adm.0000000000001158.Peer-Reviewed Original ResearchIncidence of Precipitated Withdrawal During a Multisite Emergency Department–Initiated Buprenorphine Clinical Trial in the Era of Fentanyl
D’Onofrio G, Hawk K, Perrone J, Walsh S, Lofwall M, Fiellin D, Herring A. Incidence of Precipitated Withdrawal During a Multisite Emergency Department–Initiated Buprenorphine Clinical Trial in the Era of Fentanyl. JAMA Network Open 2023, 6: e236108. PMID: 36995717, PMCID: PMC10064247, DOI: 10.1001/jamanetworkopen.2023.6108.Peer-Reviewed Original ResearchNIH HEAL Common Data Elements (CDE) implementation: NIH HEAL Initiative IDEA-CC
Adams M, Hurley R, Siddons A, Topaloglu U, Wandner L, Adams M, Arnsten J, Bao Y, Barry D, Becker W, Fiellin D, Fox A, Ghiroli M, Hanmer J, Horn B, Hurlocker M, Jalal H, Joseph V, Merlin J, Murray-Krezan C, Pearson M, Rogal S, Starrels J, Bachrach R, Witkiewitz K, Vasquez A. NIH HEAL Common Data Elements (CDE) implementation: NIH HEAL Initiative IDEA-CC. Pain Medicine 2023, 24: 743-749. PMID: 36799548, PMCID: PMC10321760, DOI: 10.1093/pm/pnad018.Peer-Reviewed Original ResearchConceptsClinical trialsClinical Trials NetworkCDE programsChronic painSecondary data analysisPainTrials NetworkDisease statesOpioidData standardsGeographical codingClinical researchHealing initiationData elementsNational InstituteTrialsDisordersFederal investmentInterventionStandard processDisorder researchSurveyed librariesCDELeveraging toolsNetwork alignmentConcordance between controlled substance receipt and post-mortem toxicology in opioid-detected overdose deaths: A statewide analysis
Howell B, Black A, Grau L, Lin H, Greene C, Lee H, Heimer R, Hawk K, D'Onofrio G, Fiellin D, Becker W. Concordance between controlled substance receipt and post-mortem toxicology in opioid-detected overdose deaths: A statewide analysis. Drug And Alcohol Dependence 2023, 244: 109788. PMID: 36738634, PMCID: PMC9975083, DOI: 10.1016/j.drugalcdep.2023.109788.Peer-Reviewed Original ResearchConceptsPost-mortem toxicologyOverdose deathsChief Medical ExaminerBenzodiazepine prescribingBenzodiazepine prescriptionsPrimary outcomePreventable deathsOpioid overdosesOpioidsAddiction servicesBenzodiazepinesMental healthStudy periodDeathMedical examinersConcordanceStatewide analysisSubstantial numberReceiptDaysDepartmentMedicationsToxicologyFentanylPrescribing